药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

未开盘 11-09 16:08:05

71.450

+0.850

+1.20%

最高73.400	最低70.700	成交量251.49万
今开71.600	昨收70.600	日振幅3.82%
总市值908.13亿	流通市值908.13亿	总股本12.71亿
成交额1.81亿	换手率0.20%	流通股本12.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":71.45,"timestamp":1794211685005,"preClose":70.6,"halted":0,"volume":2514854,"delay":0,"changeRate":0.012039660056657346,"floatShares":1271000000,"shares":1271000000,"eps":1.119999,"marketStatus":"未开盘","change":0.85,"latestTime":"11-09 16:08:05","open":71.6,"high":73.4,"low":70.7,"amount":181221401,"amplitude":0.038244,"askPrice":71.45,"askSize":1500,"bidPrice":71.2,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":1.393408732,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794274200000},"marketStatusCode":0,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":70.6,"openAndCloseTimeList":[[1794187800000,1794196800000],[1794200400000,1794211200000]],"volumeRatio":0.4027890702319949,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"1170541773","title":"异动解读｜药明合联盘中上涨3.54%，CXO与生命科学工具板块走强带动股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1170541773","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170541773?lang=zh_cn&edition=full","pubTime":"2026-11-09 10:16","pubTimestamp":1794190614,"startTime":"0","endTime":"0","summary":"11月9日，药明合联盘中上涨3.54%，报73.1港元/股，成交额3490.27万港元。消息面上，CXO与生命科学工具板块整体走强，带动公司股价上行。同板块个股中，金斯瑞生物-一千上涨5.79%，药明生物上涨4.83%，英矽智能上涨4.75%，晶泰控股上涨3.67%，药明康德上涨3.1%。公司此前披露中期业绩显示，营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；近期月报还显示，10月因购股权行权增发48.06万股，已发行股份总数增至12.7098亿股。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联盘中上涨，CXO板块集体走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105529499","title":"异动解读｜药明合联盘中下跌3.67%，生命科学工具和服务板块走弱拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1105529499","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105529499?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:42","pubTimestamp":1793929364,"startTime":"0","endTime":"0","summary":"11月6日，药明合联盘中下跌3.67%，报69.4港元/股，成交额7949.96万港元。消息面上，生命科学工具和服务板块整体走弱，药明系及CXO相关个股普遍承压，带动公司股价回落。板块内药明生物下跌3.49%，药明康德下跌2.79%，康龙化成下跌4.28%，英矽智能下跌7.26%，金斯瑞生物-一千下跌10.81%。公司此前中期实现营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；另据最新月报，10月因期权行权增发48.06万股股份。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联盘中走弱，CXO板块承压拖累股价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179867617","title":"药明合联10月股份变动月报：股本增至12.7098亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1179867617","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179867617?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:07","pubTimestamp":1793869632,"startTime":"0","endTime":"0","summary":"药明合联于2026年11月5日发布截至2026年10月31日的股份变动月报。公告显示，公司法定股本与注册股本未发生变化，注册股本维持在10,000,000,000股，面值0.00005美元，对应总注册资本500,000美元。本月底，公司普通股已发行股份总数由9月底的1,270,498,306股增加至1,270,978,936股，增幅为480,630股。新增发行主要源于2021年及2023年首次公开发售前购股权计划下的部分行使，行权价格由每股1.658元人民币至6.900元人民币不等。截至10月底，公司未发生任何股份回购或注销活动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177196473","title":"异动解读｜药明合联盘中上涨3.07%，CXO与生命科学工具板块走强带动股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1177196473","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177196473?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:57","pubTimestamp":1793843867,"startTime":"0","endTime":"0","summary":"11月5日，药明合联盘中上涨3.07%，报73.85港元/股，成交额9736.58万港元。消息面上，港股医药与CXO板块延续强势，药明系个股集体走高，带动公司股价上行。盘面显示，同板块中康龙化成上涨6.88%，药明生物上涨3.44%，药明康德上涨3.44%，英矽智能上涨2.59%。公司此前中期实现营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；高盛此前给予买入评级，目标价97.90港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联放量上攻，CXO板块集体走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118961689","title":"恒指午后走强涨超1%，创新药概念股强势拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=1118961689","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118961689?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:39","pubTimestamp":1793770784,"startTime":"0","endTime":"0","summary":"11月4日，恒指午后走强涨超1%，创新药概念股强势拉升，$药明生物(02269)$、$药明康德(02359)$涨超9%，$荣昌生物(09995)$、$百济神州(ONC)$涨超8%，$药明合联(02268)$涨超7%，$信达生物(01801)$、$康方生物(09926)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518857.USD","LU1188198961.HKD","02800","LU2399975544.HKD","LU1328277881.USD","03037","LU1242518931.SGD","LU0708995583.HKD","BK1576","LU2328871848.SGD","LU0516423091.SGD","LU0348783233.USD","BK1588","LU3063872942.SGD","IE00BFMHRM44.USD","KURE","LU1813983027.USD","LU0043850808.USD","LU0326950275.SGD","LU1251922891.USD","MCHmain","LU0244354667.USD","LU0149721374.USD","BK1610","LU0594300179.USD","LU1303224171.USD","07300","BK4139","LNGR","LU0561508036.HKD","LU0417516571.SGD","LU1720050803.USD","IE00BPRC5H50.USD","LU0516422952.EUR","LU0140636845.USD","LU0543330566.HKD","LU0634319403.HKD","LU0417516902.SGD","LU0348735423.USD","LU0039217434.USD","LU0819121731.USD","02359","IE00B5MMRT66.SGD","LU0181495838.USD","02269","LU2125910500.SGD","LU0348784397.USD","06978","06160","LU2778985437.USD","HHImain","BK4526","159992","HSImain","09115","IE00B543WZ88.USD","LU0572944931.SGD","LU0708995153.HKD","BK1583","LU1831875114.USD","LU0456827905.SGD","LU1770034418.SGD","BK4588","LU0229945570.USD","LU0502904849.HKD","LU0516422440.USD","03115","LU2476274308.USD","LU0307460666.USD","LU0828237510.HKD","LU0359202008.SGD","LU2039709279.SGD","83115","SG9999011746.SGD","LU1481107354.HKD","LU0072913022.USD","LU0348827113.USD","82800","LU0052750758.USD","MHImain","LU1794554557.SGD","ONC","LU1961090484.USD","SG9999002463.SGD","LU0320764243.SGD","LU1688375341.USD","513600","LU0469268626.HKD","BK4585","LU1719994722.HKD","LU0588546209.SGD","LU0607220059.USD","SG9999002562.SGD","LU0516423174.USD","LU2242644610.SGD","LU1969619763.USD","LU0650527681.SGD","02833","BK1141","LU0128522744.USD","LU0463099449.HKD","LU0516422366.SGD","LU0314109678.HKD","LU0128526141.USD","LU0501845795.SGD","LU2045819591.USD","LU2097828805.USD","LU0540923850.HKD","HSI","03419","LU0149534421.HKD","LU2476274720.SGD","LU0455707207.USD","LU0856984785.SGD","LU0164880469.USD","LU2097828474.EUR","IBBQ","LU0320764599.SGD","LU2097828631.EUR","SG9999014674.SGD","LU0348767384.USD","BK1521","HK0000165453.HKD","LU1880383366.USD","LU0348766576.USD","LU0348825331.USD","LU2097828557.USD","09926","07200","LU0029874905.USD","LU0211977185.USD","LU0605514214.HKD","02268","LU0228659784.USD","LU0327786744.USD","LU0823426308.USD","LU1046422090.SGD","LU0456846285.SGD","07500","LU0594300419.USD","09995","IE00B0JY6N72.USD","LU2097828714.EUR","LU0979878070.USD","MEDX","01801","BK1589","LU0823426480.USD","LU2488822045.USD","BK1574","LU0029874061.USD","LU0051755006.USD","BK1161","LU0359201612.USD","BK1500","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680519700","title":"CXO板块逆市走强 百济神州（06160）涨5.14%、凯莱英（06821）涨4.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680519700","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680519700?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:34","pubTimestamp":1793759693,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块逆市走强，百济神州 涨5.14%，凯莱英涨4.19%，药明康德涨3.92%，药明生物涨3.58%，科伦博泰生物涨2.89%，药明合联涨2.44%，和铂医药-B涨1.76%，康龙化成涨1.46%，和黄医药涨1.17%。湘财证券表示，CXO龙头药明康德三季报超预期、指引上修，印证CXO由周期修复转向CRDMO结构性重估。维持药品行业“买入”评级，建议关注创新化学制剂及创新药产业链上游CXO公司。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995187","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WX","LU0051755006.USD","02268","LU2476274720.SGD","CXO","LU1720050803.USD","LU2476274308.USD","ONC","02359","LU0516422440.USD","LU0828237510.HKD","02269","06160","688235","LU0128522744.USD","LU0501845795.SGD","03759","LU0456827905.SGD","LU0348766576.USD","BK1574","LU0823426480.USD","LU0455707207.USD","BK0132","SG9999002562.SGD","LU0043850808.USD","LU0359202008.SGD","LU0502904849.HKD","LU2045819591.USD","02142","KURE","LU0072913022.USD","LU0229945570.USD","LU0823426308.USD","LU0588546209.SGD","SG9999002463.SGD","06990","LU0327786744.USD","LU0320764243.SGD","LU3063872942.SGD","00013","BK1141","LU1831875114.USD","LU0463099449.HKD","002821","LU0516423091.SGD","LU0326950275.SGD","06821","LU1242518857.USD","LU0128526141.USD","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680020457","title":"生物医药板块盘初走高 百济神州（06160）涨4.66%、药明生物（02269）涨3.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680020457","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680020457?lang=zh_cn&edition=full","pubTime":"2026-11-04 09:53","pubTimestamp":1793757224,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块盘初走高，截至发稿，百济神州 涨4.66%，药明生物涨3.99%，荣昌生物涨3.60%，药明康德涨3.52%，康方生物涨3.37%，再鼎医药涨2.43%，复宏汉霖涨2.37%，药明合联涨2.05%，泰格医药涨1.58%。华安证券研究指出，2026年三季度，医药板块跑赢大市、利润逐季加速。展望后市，该机构预计CXO、创新药、医疗器械与低基数修复。血制品、品牌中药三季度收入仍在下降。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995176","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0164880469.USD","BK1588","ONC","LU0348767384.USD","LU0140636845.USD","LU0455707207.USD","03347","IE00BPRC5H50.USD","LU2045819591.USD","LU0211977185.USD","BK4585","LU1794554557.SGD","LU0417516571.SGD","LU0516422440.USD","LU0543330566.HKD","LU1813983027.USD","LU0469268626.HKD","09995","LU1969619763.USD","09926","HK0000320223.HKD","02696","06160","LU0417516738.SGD","09688","LU0229945570.USD","XBI","LU0052750758.USD","LU0029874061.USD","LU0540923850.HKD","LU0979878070.USD","LU0516422952.EUR","688235","BK0239","SG9999002463.SGD","IE00BFMHRM44.USD","LU0456846285.SGD","LU2778985437.USD","BK1589","LU0463099449.HKD","161726","LU0348827113.USD","02268","02359","LU0029874905.USD","LU0823426480.USD","399441","02269","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102887943","title":"异动解读｜药明合联盘中上涨3.15%，生命科学工具和服务板块走强带动股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1102887943","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102887943?lang=zh_cn&edition=full","pubTime":"2026-11-04 09:43","pubTimestamp":1793756607,"startTime":"0","endTime":"0","summary":"11月4日，药明合联盘中上涨3.15%，报65.4港元/股，成交额2476.93万港元。从公开信息看，公司近期未见新增明确独立利好，本次走强更接近生命科学工具和服务板块联动上涨所致。板块内个股同步走强，药明生物上涨5.29%，康龙化成上涨5.0%，药明康德上涨4.38%，金斯瑞生物-一千上涨2.25%，英矽智能上涨0.87%。此前公司中期实现营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；高盛此前给予买入评级，目标价97.90港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联上涨，生命科学板块联动走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105366625","title":"异动解读｜药明合联盘中下跌3.41%，生命科学工具服务板块走弱拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1105366625","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105366625?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:39","pubTimestamp":1793669986,"startTime":"0","endTime":"0","summary":"11月3日，药明合联盘中下跌3.41%，报63.65港元/股，成交额1804.34万港元。从已披露信息看，公司近期未见新增明确利空，本次回落更接近生命科学工具和服务板块联动走弱所致。同板块个股普遍承压，药明康德下跌2.89%，英矽智能下跌2.74%，晶泰控股下跌2.33%，药明生物下跌0.9%，金斯瑞生物-一千下跌11.02%。公司此前中期营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；此前亦获机构给予买入评级，目标价97.90港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联盘中走弱，生命科学板块承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102757670","title":"异动解读｜药明合联盘中下跌3.08%，生命科学工具服务板块走弱拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1102757670","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102757670?lang=zh_cn&edition=full","pubTime":"2026-11-02 10:54","pubTimestamp":1793588096,"startTime":"0","endTime":"0","summary":"11月2日，药明合联盘中下跌3.08%，报64.6港元/股，成交额1.36亿港元。从已披露信息看，公司近期未见新增明确利空，本次回落更接近生命科学工具和服务板块联动走弱所致。板块内个股同步偏弱，药明康德下跌3.29%，晶泰控股下跌3.19%，金斯瑞生物-一千下跌2.68%，药明生物下跌0.49%。公司此前中期营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；机构此前给予买入评级，目标价97.90港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联随板块走弱下跌，机构目标价仍看近百港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680786312","title":"【券商聚焦】中信建投：中国医药资产全球性价比凸显，内外协同空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2680786312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680786312?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:46","pubTimestamp":1793580413,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报称，2026年欧洲内科肿瘤学会 中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。该机构指，中国医药具有“创新升级+供应链韧性”优势，2025年创新药海外授权首付款大幅超去年全年，器械也在积极探索出海路径。美国主导早期研发与高端定价，但跨国药企专利悬崖下需求旺盛，中国资产全球性价比凸显，内外协同空间广阔。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","LU2476274308.USD","LU1969619763.USD","BK1515","LU0540923850.HKD","SG9999004311.SGD","601066","IE00B5MMRT66.SGD","BK0188","03069","LU2476274720.SGD","01530","LU2399975544.HKD","03933","09926","01789","LU0634319403.HKD","BK1610","LU0228659784.USD","LU0348825331.USD","LU0588546209.SGD","01099","BK1617","600056","BK1161","LU0348783233.USD","LU0348767384.USD","09688","LU0417516902.SGD","LU0348766576.USD","LU0348735423.USD","IE00BPRC5H50.USD","LU0307460666.USD","02367","LU1251922891.USD","KCE","LU2488822045.USD","SG9999014674.SGD","BK0028","02268","KURE","02196","06821","LU1720050803.USD","02228","BK1141","LU0561508036.HKD","06160","BK1207","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券：国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略，“十五五”开局之年，医药行业首次列为国家新兴支柱产业，紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势，叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下，该机构看到2026H1国内医药板块业绩持续修复，尤其是创新药、创新器械等新兴产业板块。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","00013","LU2488822045.USD","LU1226287529.USD","06821","LU0348766576.USD","06078","159938","06160","IE00B031HY20.USD","KURE","LU0607220059.USD","02268","02596","LU0708995153.HKD","HK0000320264.USD","LU0039217434.USD","LU1794554557.SGD","01276","LU0979878070.USD","01548","09939","LU0348825331.USD","01093","02162","01951","02269","LU0588546209.SGD","02096","01177","LU1969619763.USD","09966","06996","LU0455707207.USD","03692","LU0823426480.USD","06990","06030","LU1064131003.USD","LU0708995583.HKD","03759","LU0828237510.HKD","BK0028","02273","01801","09996","09926","KCE","01952","600030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147723449","title":"异动解读｜药明合联盘中下跌3.02%，生命科学工具服务板块走弱拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1147723449","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147723449?lang=zh_cn&edition=full","pubTime":"2026-10-30 09:46","pubTimestamp":1793324775,"startTime":"0","endTime":"0","summary":"10月30日，药明合联盘中下跌3.02%，报66.3港元/股，成交额2294.86万港元。从已披露信息看，公司近期未见新增明确利空，本次回落更接近生命科学工具和服务板块联动走弱所致。同业个股中，晶泰控股下跌3.05%，药明生物下跌1.86%，英矽智能下跌1.75%，药明康德下跌1.73%，金斯瑞生物-一千下跌8.49%。公司此前中期营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；机构此前给予买入评级，目标价97.90港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联盘中下挫，板块联动拖累股价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186213054","title":"异动解读｜药明合联盘中下跌3.03%，生命科学工具服务板块走弱拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1186213054","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186213054?lang=zh_cn&edition=full","pubTime":"2026-10-29 10:17","pubTimestamp":1793240255,"startTime":"0","endTime":"0","summary":"10月29日，药明合联盘中下跌3.03%，报67.15港元/股，成交额6792.66万港元。从已披露信息看，公司近期未见新增明确利空，本次回落更接近生命科学工具和服务板块联动走弱所致。同业个股中，药明生物下跌3.2%，昭衍新药下跌5.88%，英矽智能下跌1.91%，药明康德下跌1.63%，仅金斯瑞生物-一千上涨1.8%。公司中期营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；此前机构给予买入评级，目标价97.90港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联随板块走弱，盘中下探引发关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165063623","title":"异动解读｜药明合联盘中下跌3.76%，生命科学工具服务板块走弱拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1165063623","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165063623?lang=zh_cn&edition=full","pubTime":"2026-10-27 10:05","pubTimestamp":1793066732,"startTime":"0","endTime":"0","summary":"10月27日，药明合联盘中下跌3.76%，报67.8港元/股，成交额1.78亿港元。从已披露信息看，公司近期未见新增明确利空，本次回落更接近生命科学工具和服务板块联动走弱所致。同业个股中，药明生物下跌4.71%，英矽智能下跌1.37%，药明康德下跌1.33%，晶泰控股下跌0.25%，仅金斯瑞生物-一千上涨4.04%。公司此前中期营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；机构此前给予买入评级，目标价97.90港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联盘中走低，生命科学板块联动承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184935453","title":"异动解读｜药明合联盘中下跌3.16%，生命科学工具服务板块走弱拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1184935453","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184935453?lang=zh_cn&edition=full","pubTime":"2026-10-26 10:19","pubTimestamp":1792981182,"startTime":"0","endTime":"0","summary":"10月26日，药明合联盘中下跌3.16%，报69.05港元/股，成交额5017.39万港元。从已披露信息看，公司近期未见新增明确利空，本次回落更接近生命科学工具和服务板块联动走弱所致。同业个股中，英矽智能下跌3.35%，药明生物下跌1.4%，药明康德下跌0.81%，金斯瑞生物-一千下跌0.7%，晶泰控股下跌0.41%。公司此前中期业绩显示，上半年营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；此前机构给予买入评级，目标价97.90港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联走弱，板块联动承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126932620","title":"异动解读｜药明合联盘中下跌3.05%，生命科学工具服务板块回调拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1126932620","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126932620?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:37","pubTimestamp":1792719450,"startTime":"0","endTime":"0","summary":"10月23日，药明合联盘中下跌3.05%，报66.8港元/股，成交额3531.19万港元。从公开信息看，公司近期未见新增明确利空，此次走弱更接近生命科学工具和服务板块整体承压所致。同板块个股中，金斯瑞生物-一千跌9.73%，英矽智能跌4.67%，晶泰控股跌3.76%，药明生物跌3.05%，药明康德跌2.12%。公司此前中期营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；此前机构曾给出买入评级，目标价97.90港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联随板块走弱，盘中回调显压力","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184206329","title":"异动解读｜药明合联盘中下跌3.15%，板块回调拖累股价走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1184206329","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184206329?lang=zh_cn&edition=full","pubTime":"2026-10-22 10:21","pubTimestamp":1792635701,"startTime":"0","endTime":"0","summary":"10月22日，药明合联盘中下跌3.15%，报73.75港元/股，成交额7719.07万港元。从已披露信息看，公司近期无新增明确利空事件，股价走弱更接近板块联动。其所处生命科学工具和服务板块当日普遍承压，药明生物下跌4.01%，药明康德下跌1.89%，英矽智能下跌6.68%，晶泰控股下跌3.03%，金斯瑞生物-一千下跌0.76%。公司此前中期业绩显示，上半年营收37.01亿元，同比增长37.0%，经调整净利润10.27亿元，同比增长37.4%；高盛此前维持买入评级，目标价97.90港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联随板块走弱，盘中承压下跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676665575","title":"创新药概念强势 翰森制药（03692）涨逾7% 前三季对外技术授权约1300亿美元接近25年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665575","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665575?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:23","pubTimestamp":1792466598,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念强势，截至发稿，乐普生物 涨8.81%，翰森制药涨7.06%，药明生物涨6.74%，晶泰控股涨4.56%，康诺亚-B涨4.70%，亚盛医药涨4.30%，恒瑞医药涨4.16%，药明合联涨3.96%，云顶新耀涨3.89%，和黄医药涨3.68%，中国生物制药涨3.24%，石药集团涨3.16%，科伦博泰生物涨3.14%，诺诚健华涨3.08%。消息面上，据人民财讯，10月20日，国家发展改革委召开10月份新闻发布会，会上提到，我国前三季度创新药对外技术授权约1300亿美元，接近去年全年。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516738.SGD","BK1589","LU1008478684.HKD","LU1242518857.USD","06978","01177","01952","02157","LU0128522744.USD","IE0008369823.USD","LU1226288170.HKD","LU1242518931.SGD","BK1161","BK1610","IBBQ","LU0348827113.USD","LU1152091754.HKD","06990","LU0043850808.USD","01093","LU0417516902.SGD","LU0211977185.USD","LU0196878994.USD","02268","LU1720050803.USD","01276","09969","06855","LU0072913022.USD","MEDX","02269","LU0588546209.SGD","LU1794554557.SGD","LU0359201885.HKD","LNGR","02228","LU2488822045.USD","LU0979878070.USD","BK1576","159992","LU1188198961.HKD","00013","LU0052750758.USD","02162","BK1521","KURE","LU2543165471.USD","03692","LU2476274720.SGD","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175200909","title":"异动解读｜药明合联盘中上涨3.63%，ADC与CXO景气预期提振板块","url":"https://stock-news.laohu8.com/highlight/detail?id=1175200909","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175200909?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:57","pubTimestamp":1792465020,"startTime":"0","endTime":"0","summary":"10月20日，药明合联盘中上涨3.63%，报77.15港元/股，成交额1.49亿港元。消息面上，ADC产业链再获关注，翰森制药当日因与罗氏再签ADC战略合作大单而走强，叠加机构近期继续看好创新药与CXO龙头，带动药明合联所在板块情绪回暖。背景上看，公司所处ADC CRDMO赛道景气度较高，其中其上半年综合收益达37.014亿元人民币，按固定汇率同比增长41.5%；同时，机构此前提到港股及A股CXO收入分别增长29.2%和25.3%，行业订单需求处于高位，强化了市场对龙头公司的业绩预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联盘中上扬，ADC与CXO景气预期提振板块","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":0.0818},{"period":"1month","weight":-0.1297},{"period":"3month","weight":0.1121},{"period":"6month","weight":0.277},{"period":"1year","weight":0.05},{"period":"ytd","weight":0.1761}],"compareEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0735},{"period":"1year","weight":-0.0683},{"period":"ytd","weight":-0.0461}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范（GMP）生产。该公司透过按有偿服务（FFS）基准的合约和按全时当量（FTE）基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.144701},{"month":2,"riseRate":0.666667,"avgChangeRate":0.024159},{"month":3,"riseRate":0.666667,"avgChangeRate":0.102712},{"month":4,"riseRate":0.666667,"avgChangeRate":0.010649},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.091782},{"month":6,"riseRate":1,"avgChangeRate":0.069902},{"month":7,"riseRate":0.666667,"avgChangeRate":0.109892},{"month":8,"riseRate":0.666667,"avgChangeRate":0.150478},{"month":9,"riseRate":1,"avgChangeRate":0.240082},{"month":10,"riseRate":0,"avgChangeRate":-0.07959},{"month":11,"riseRate":0.666667,"avgChangeRate":0.045388},{"month":12,"riseRate":0.666667,"avgChangeRate":0.053198}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}